hVIVO (LON:HVO) Share Price Crosses Above Fifty Day Moving Average – Should You Sell?

hVIVO plc (LON:HVO)’s stock price crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of GBX 7.56 and traded as high as GBX 8.30. hVIVO shares last traded at GBX 7.88, with a volume of 2,097,438 shares.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on HVO. Shore Capital Group reiterated a “buy” rating on shares of hVIVO in a research note on Wednesday, April 22nd. Stifel Nicolaus reiterated a “hold” rating and set a GBX 10 price objective on shares of hVIVO in a research note on Thursday, May 7th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, hVIVO presently has an average rating of “Moderate Buy” and an average target price of GBX 15.

hVIVO Price Performance

The stock has a market capitalization of £54.21 million, a price-to-earnings ratio of -9.05 and a beta of 1.69. The company has a quick ratio of 1.16, a current ratio of 1.63 and a debt-to-equity ratio of 38.75. The business’s 50 day simple moving average is GBX 7.56 and its 200-day simple moving average is GBX 6.97.

hVIVO (LON:HVO) last announced its quarterly earnings data on Wednesday, April 15th. The company reported GBX (0.87) earnings per share (EPS) for the quarter. The firm had revenue of GBX 4,677 million for the quarter. hVIVO had a negative return on equity of 14.65% and a negative net margin of 12.48%. On average, research analysts forecast that hVIVO plc will post 1.5492958 earnings per share for the current year.

Insider Buying and Selling at hVIVO

In other news, insider Brendan Buckley sold 2,017,000 shares of the firm’s stock in a transaction that occurred on Friday, April 24th. The shares were sold at an average price of GBX 9, for a total value of £181,530. Insiders own 5.24% of the company’s stock.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.